CSL Limited (ASX: CSL) - Investment Research Report

3-Year / 5-Year Price Scenarios

Base EPS: $4.5 — AUD-normalised analyst base EPS anchored to FY2025 reported NPAT, the FY2026 half-year result and management's FY2026 guidance; CSL reports statutory figures in USD.

0. Information Richness & AI Limitations

Grade A for information richness, not investment certainty. CSL publishes audited accounts, results presentations and operating disclosures. The current official financial-results index lists FY2025 released 19 August 2025 and the FY2026 half-year result released 11 February 2026; it also says FY2026 full-year results were scheduled for 18 August 2026, after this 31 July cutoff. Confidence is high on published figures and the business model, but lower on the recovery timing, currency and scenario targets.

1. Data & Cross-Validation

Market snapshot at 31 July 2026: the ASX company header returned A$123.30 and a market capitalisation of approximately A$61.27B. Using 497.0M shares gives A$61.28B (price x shares), a 0.02% reconciliation difference. Yahoo Finance was throttled in this run; the ASX header is the independent live-price fallback used by the validator.

Reported USD financials: FY2025 revenue was US$15.6B, reported NPAT US$3.0B and total dividend US$2.92/share. The FY2026 half-year announcement reported revenue of US$8.3B, NPAT of US$401M and an interim dividend of US$1.30/share; underlying NPATA was US$1.9B, down 7%, with restructuring and impairment charges affecting statutory profit. The filing states FY2026 guidance of approximately 2-3% revenue growth and 4-7% NPATA growth at constant currency, excluding specified one-off costs. Figures are reported in USD; the quote and valuation are in AUD.

2. Business Essence - Duan Yongping

One line: CSL collects and fractionates human plasma, develops vaccines and supplies specialty medicines for serious diseases. Patient need is recurring and often non-discretionary; the economics depend on donor supply, manufacturing yield, regulatory quality and reimbursement rather than on ordinary consumer demand. Plasma-derived therapies create a long learning curve and scale advantage, while vaccine and specialty-pharma earnings add diversification but also more product and policy risk.

3. Moat - Buffett

The strongest moat is the regulated plasma collection and fractionation system: donor centres, quality systems, manufacturing capacity, clinical know-how and global distribution are difficult and slow to reproduce. Scale improves yield, supply resilience and cost absorption. Switching costs are meaningful for physicians and patients when therapies are life-sustaining, although payers negotiate and products compete. Brand and regulatory trust matter more than network effects. The moat is durable and can widen with collection scale, but it narrows if competitors add plasma capacity, reimbursement pressure reduces returns or supply-chain quality slips.

4. Reverse Thinking & Risks - Munger

The failure path is a prolonged plasma oversupply or collection shortfall, lower immunoglobulin pricing, manufacturing or quality failure, a vaccine setback, Vifor portfolio underperformance, or a transformation that consumes cash without restoring margins. The FY2026 first half is disconfirming evidence against a smooth compounder: reported NPAT fell sharply after policy changes, restructuring costs and impairments, while underlying NPATA declined 7%. The historical analogy is a high-quality pharmaceutical supplier that remains strategically important but loses years of returns through execution, pricing or capital-allocation mistakes. A high starting multiple magnifies disappointment.

5. Management - Duan Yongping + Buffett

CSL's long record of building plasma capacity and global biologicals capabilities demonstrates operational competence and patient capital investment. The current transformation, organisational simplification and expanded US$750M buyback show a willingness to address cost and capital structure, but the half-year impairment and restructuring burden make execution the present test. Incentives should be judged by NPATA growth, returns on plasma and specialty-pharma investment, safety and disciplined buybacks rather than by adjusted headline growth alone. Management is important here because the assets are excellent but complex to operate.

6. Industry & Civilizational Trend - Li Lu

Ageing populations, immune deficiency, chronic disease and improved diagnosis support long-run demand for plasma-derived therapies and specialty medicines. Plasma supply is the binding input, so the value chain rewards collection density and fractionation scale. Vaccines remain strategically important but are seasonal and policy-sensitive. Technology can improve yield, diagnostics and biologics, yet it does not remove the need for trusted manufacturing and biological raw material. The long-run opportunity is durable healthcare demand; the constraint is affordability, reimbursement and the finite rate at which safe plasma can be collected.

7. Valuation & Scenarios - Buffett + Duan

At A$123.30, the snapshot is approximately 27.4x the AUD-normalised A$4.50 base EPS and the cash yield is about 2.2%. That is a quality premium, not a distressed price. The analyst scenarios use 25% bull, 50% base and 25% bear probabilities. Three-year: A$170 bull, A$145 base and A$80 bear produce a weighted A$135.00, or +9.5% before dividends. Five-year: A$210 bull, A$165 base and A$75 bear produce a weighted A$153.75, or +24.7% before dividends. The main uncertainties are plasma supply and pricing, recovery timing, restructuring execution, product launches, reimbursement, USD/AUD and the exit multiple. These are calculations, not company guidance.

8. Decision Memo

Stance: watchlist. CSL is a high-quality business with a rare moat, but the current quote does not provide enough margin of safety while first-half NPATA is declining and the transformation remains unfinished. Prefer staged buying around A$95-A$110 or when the same margin of safety appears through earnings recovery. Add when plasma volumes and margins improve, guidance is delivered and restructuring benefits become visible. Reassess or sell if pricing power, quality, donor supply or capital discipline deteriorate. The thesis is invalidated by a structural return-on-capital decline, not by one noisy half-year.

Four-Master Commentary

These are analytical simulations, not real quotations.

Buffett simulation: Plasma collection and fractionation are scarce, regulated capabilities with recurring medical demand. The moat is real, but a great business can still be a poor purchase at a full multiple.

Munger simulation: Invert it: supply, reimbursement, quality failure and restructuring can destroy returns faster than the headline healthcare story can repair them. Watch the adjusted-to-statutory bridge.

Duan Yongping simulation: The business has a durable operating system, but management must prove that simplification and buybacks create value rather than mask weak underlying growth.

Li Lu simulation: CSL sits in a long-run healthcare value chain supported by ageing and chronic disease. The opportunity is durable biological demand, while the constraint is plasma supply, affordability and regulation.